SK Biopharmaceuticals signed an AI-driven collaboration with Insilico Medicine valued at more than $2.5 billion to accelerate neuroimmune disorder drug discovery in the CNS. The milestone-heavy partnership, announced during BIO 2026, pairs Insilico’s Pharma.AI platform with SK Biopharm’s CNS development and commercialization capabilities. The deal underscores how large biotechs are embedding AI into both early target discovery and development planning, aiming to compress discovery and selection cycles for CNS programs where biological complexity can slow iteration. As presented at BIO, SK framed the collaboration as a way to move faster across discovery stages, while Insilico’s economics reflect the market’s willingness to pay for AI-enabled pipeline acceleration under milestone structures.